Zentalis Pharmaceuticals, Inc. DEF 14A Filing
Ticker: ZNTL · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1725160
Sentiment: neutral
Topics: DEF 14A, Zentalis Pharmaceuticals, Executive Compensation, Corporate Governance, SEC Filing
TL;DR
<b>Zentalis Pharmaceuticals, Inc. files DEF 14A detailing executive compensation and corporate governance for the reporting period ending June 21, 2024.</b>
AI Summary
Zentalis Pharmaceuticals, Inc. (ZNTL) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Filing Type: DEF 14A. Reporting Period: 2024-06-21. Filed As Of Date: 2024-04-29. Fiscal Year End: 12-31. SIC Code: 2834 (Pharmaceutical Preparations).
Why It Matters
For investors and stakeholders tracking Zentalis Pharmaceuticals, Inc., this filing contains several important signals. This filing provides crucial information regarding executive compensation, which can impact investor decisions and company performance. Understanding the details of this DEF 14A filing is important for shareholders to assess management's alignment with company interests and financial health.
Risk Assessment
Risk Level: low — Zentalis Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, which typically contains standard disclosures about executive compensation and corporate governance, with no immediate red flags.
Analyst Insight
Review the executive compensation details and any proposed shareholder actions to inform investment strategy.
Key Numbers
- 2024-06-21 — Reporting Period End Date (Conformed Period of Report)
- 2024-04-29 — Filed As Of Date (Filed As Of Date)
- 1231 — Fiscal Year End (Fiscal Year End)
- 2834 — SIC Code (Standard Industrial Classification)
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Filer name
- 0001725160 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification
- 1359 BROADWAY, SUITE 801 (company) — Business Address
- New York (company) — Business Address City
- 10018 (company) — Business Address Zip
- Zentalis Pharmaceuticals, LLC (company) — Former Company Name
- Zeno Pharma, LLC (company) — Former Company Name
FAQ
When did Zentalis Pharmaceuticals, Inc. file this DEF 14A?
Zentalis Pharmaceuticals, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Zentalis Pharmaceuticals, Inc. (ZNTL).
Where can I read the original DEF 14A filing from Zentalis Pharmaceuticals, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Zentalis Pharmaceuticals, Inc..
What are the key takeaways from Zentalis Pharmaceuticals, Inc.'s DEF 14A?
Zentalis Pharmaceuticals, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: Filing Type: DEF 14A. Reporting Period: 2024-06-21. Filed As Of Date: 2024-04-29.
Is Zentalis Pharmaceuticals, Inc. a risky investment based on this filing?
Based on this DEF 14A, Zentalis Pharmaceuticals, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A, which typically contains standard disclosures about executive compensation and corporate governance, with no immediate red flags.
What should investors do after reading Zentalis Pharmaceuticals, Inc.'s DEF 14A?
Review the executive compensation details and any proposed shareholder actions to inform investment strategy. The overall sentiment from this filing is neutral.
How does Zentalis Pharmaceuticals, Inc. compare to its industry peers?
Zentalis Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of novel cancer therapeutics.
Are there regulatory concerns for Zentalis Pharmaceuticals, Inc.?
The DEF 14A filing is a proxy statement required by the SEC for publicly traded companies, providing shareholders with information to vote on corporate matters.
Industry Context
Zentalis Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of novel cancer therapeutics.
Regulatory Implications
The DEF 14A filing is a proxy statement required by the SEC for publicly traded companies, providing shareholders with information to vote on corporate matters.
What Investors Should Do
- Analyze the compensation structure for named executive officers.
- Review any proposals submitted for shareholder vote.
- Assess the company's governance practices outlined in the filing.
Key Dates
- 2024-06-21: Reporting Period End — Defines the period covered by the filing.
- 2024-04-29: Filing Date — Date the document was officially submitted to the SEC.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a routine disclosure and does not represent a change from previous filings of the same type, but provides updated information for the current period.
Filing Stats: 4,904 words · 20 min read · ~16 pages · Grade level 11.4 · Accepted 2024-04-29 16:34:30
Key Financial Figures
- $0.001 — ng share of our common stock, par value $0.001 per share (Nasdaq: ZNTL), or our Common
Filing Documents
- zntl-20240429.htm (DEF 14A) — 943KB
- zntl-20240429_g1.jpg (GRAPHIC) — 3KB
- zntl-20240429_g2.jpg (GRAPHIC) — 67KB
- zntl-20240429_g3.jpg (GRAPHIC) — 100KB
- zntl-20240429_g4.jpg (GRAPHIC) — 6KB
- zntl-20240429_g5.jpg (GRAPHIC) — 23KB
- zntl-20240429_g6.jpg (GRAPHIC) — 298KB
- zntl-20240429_g7.jpg (GRAPHIC) — 281KB
- zntl-20240429_g8.jpg (GRAPHIC) — 455KB
- zntl-20240429_g9.jpg (GRAPHIC) — 230KB
- 0001725160-24-000096.txt ( ) — 5080KB
- zntl-20240429.xsd (EX-101.SCH) — 3KB
- zntl-20240429_def.xml (EX-101.DEF) — 4KB
- zntl-20240429_lab.xml (EX-101.LAB) — 4KB
- zntl-20240429_pre.xml (EX-101.PRE) — 3KB
- zntl-20240429_htm.xml (XML) — 215KB
EXECUTIVE COMPENSATION TABLES
EXECUTIVE COMPENSATION TABLES 40 DIRECTOR COMPENSATION 60 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 62
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 63 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 66 OTHER MATTERS 69 5 ZENTALIS PHARMACEUTICALS, INC. 1359 Broadway, Suite 801 New York, New York 10018 PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on Friday, June 21, 2024 at 9:00 a.m. Eastern Time GENERAL INFORMATION This Proxy Statement, along with the accompanying Notice of 2024 Annual Meeting of Stockholders, contains information about the 2024 Annual Meeting of Stockholders of Zentalis Pharmaceuticals, Inc., including any postponement or adjournment of the meeting, which we refer to as the Annual Meeting. We are holding the Annual Meeting on Friday, June 21, 2024, at 9:00 a.m. Eastern Time, or ET. The Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/ZNTL2024 and entering your 16-digit control number included in your Notice of Internet Availability of Proxy Materials, or the Internet Notice, on your proxy card or on the instructions that accompanied your proxy materials. The mailing of the Internet Notice to our stockholders is scheduled to begin on or around April 29, 2024. The record date for the Annual Meeting is April 23, 2024, or the Record Date. You are entitled to notice of the Annual Meeting, and any postponement or adjournment, only if you were a stockholder of record of shares of our common stock, $0.001 par value per share, or our Common Stock, as of 5:00 p.m. ET on the Record Date. You are entitled to vote at the Annual Meeting, and any postponement or adjournment, only if you were a stockholder of record of shares of our Common Stock as of 5:00 p.m. ET on the Record Date, or if you hold a valid proxy for the Annual Meeting. As of the Record Date, there were 71,013,233 shares of Common Stock outstanding